Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Withdrawn 2Terminated 1Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 1

Conditions

Lymphoma, Non-Hodgkin 5Breast Neoplasms 5Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma 4Leukemia, Myeloid, Acute 4Hodgkin Disease 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sezary Syndrome 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Parathyroid Neoplasms 2Otorhinolaryngologic Neoplasms 2Osteosarcoma 2Neoplasms 2Mixed Tumor, Mesodermal 2Mesothelioma, Cystic 2

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × belinostat × Clear all
NCT02679131 2019-11-20

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Acrotech Biopharma Inc.

Phase 1 Terminated
18 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms, Renal Insufficiency

NCT02875002 2017-12-22

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Yale University

Phase 1 Withdrawn
Lymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT02532192 2016-01-06

A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00351975 2014-12-23

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

National Cancer Institute (NCI)

Phase 1 Completed
56 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡